Pharmaceutical Strategies Group
Actinium Pharmaceuticals, based in New York City, specializes in the development of Antibody Radiation Conjugates (ARCs) and targeted radiotherapies aimed at improving outcomes for patients who have not responded to existing oncology treatments. With advanced candidates like Actimab-A for acute myeloid leukemia (AML) and Iomab-ACT for cell and gene therapies, Actinium is committed to enhancing patient access and therapeutic efficacy.
The company holds 230 patents related to its technologies, including innovations in the manufacture of Ac-225 isotopes. Actinium's research and development initiatives also include several preclinical programs focused on solid tumor indications, highlighting its robust pipeline and commitment to oncology advancements.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.


